Clinical TrialAug 11, 2026, 04:09 PM
Clearmind Medicine Reports Positive Intranasal MEAI Permeation Results
AI Summary
Clearmind Medicine Inc. announced positive permeation study results for its intranasal MEAI formulation, confirming that enhanced nasal retention does not compromise drug delivery. The findings indicate that the formulation maintains efficient drug transport while extending nasal residence time. This supports the continued development of the intranasal program for potential treatments for alcohol use disorder, weight management, obesity, and metabolic conditions.
Key Highlights
- Clearmind Medicine announced positive permeation study results for its intranasal MEAI formulation.
- Enhanced nasal retention of the proprietary formulation did not compromise MEAI's permeation.
- Cumulative permeation for intranasal MEAI reached 97.35% by 180 minutes.
- Conventional MEAI formulation achieved 98.34% cumulative permeation by 180 minutes.
- The formulation demonstrated successful integration, enhanced mucoadhesion, and preserved permeation kinetics.
- Results support continued development for alcohol use disorder, weight management, obesity, and metabolic conditions.
Price Impact
More from CMND